ALDERIA INTELLIGENCE
← All signals
PubMed15 Apr 2026Circulation research● 6/10i

Reversible Fibroblast Trajectories Regulated by MR Underlie Diastolic Dysfunction.

Meral D, Mamazhakypov A, Koca D, Mukherjee D, Kamaras C et al.

Mineralocorticoid receptor (MR) activation in cardiac fibroblasts drives diastolic dysfunction in heart failure with preserved ejection fraction (HFpEF) through a distinct fibroblast subtype different from myofibroblasts in heart failure with reduced ejection fraction. Preclinical study in male and female mice using aldosterone/high-salt diet and high-fat diet models, with single-nucleus RNA sequencing and fibroblast-specific MR deletion experiments. This provides the first mechanistic evidence that MR antagonists' clinical benefits in HFpEF operate through fibroblast-specific pathways rather than cardiomyocyte effects. The reversible nature of aldosterone-induced changes suggests potential for disease modification with MR antagonist therapy.

Strategic Signal

This mechanistic validation strengthens the clinical rationale for MR antagonists in HFpEF, where spironolactone and finerenone have shown modest but meaningful benefits in recent trials. The fibroblast-specific mechanism differentiates HFpEF from heart failure with reduced ejection fraction, supporting targeted therapy development and potentially more precise patient selection. US and EU cardiologists gain clearer biological justification for MR antagonist use in HFpEF patients with cardiorenal or cardiometabolic comorbidities.

Cardiovascular

Original Abstract

BACKGROUND: Heart failure with preserved ejection fraction (HFpEF) is a major health issue of our time. The pathophysiology of HFpEF is diverse, linked to comorbidities, such as kidney disease or obesity, and different from heart failure with reduced ejection fraction. As a consequence, treatment options are still limited. Recent clinical trials indicate beneficial effects of MR (mineralocorticoid receptor) antagonists in HFpEF, but the underlying mechanisms are incompletely understood. METHODS AND RESULTS: We treated male and female mice with aldosterone and a high salt-diet to induce a preclinical cardiorenal HFpEF-like phenotype. Diastolic dysfunction and structural remodeling were comparable in both sexes and, of note, largely reversible after aldosterone withdrawal. Single-nucleus RNA sequencing of left ventricles indicated the greatest change in gene expression after aldosterone treatment in cardiomyocytes, endothelial cells, and fibroblasts. In response to aldosterone, we observed a shift towards a fibroblast subpopulation that is distinct from the canonical myofibroblast population typically seen in heart failure with reduced ejection fraction. Comparison with high-fat diet-induced HFpEF showed an overlapping upregulation of typical MR target genes in both models. To validate the functional consequence of this finding, we treated mice with fibroblast-specific MR deletion (MRTCF21Cre). In contrast to a previous study in heart failure with reduced ejection fraction, MR deletion prevented the onset of diastolic dysfunction, suggesting different roles for fibroblast MR in heart failure subtypes. CONCLUSIONS: Diastolic dysfunction is associated with a fibroblast subtype that is different from the myofibroblasts observed in heart failure with reduced ejection fraction. MR activation is an overlapping feature of cardiorenal and cardiometabolic disease models. Further, MR deletion from fibroblasts prevents disease progression, suggesting that the beneficial effects of MR antagonists in HFpEF are related to inhibition of fibroblast MR.

Related signals

Strategic Signal

Clinical Trial17 Apr 2026Phase 3High impact● 8/10i

A Phase 3, Open-Label Study of Once Daily LY3502970 Compared With Insulin Glargine in Adult Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

Phase 3 open-label trial compared once-daily oral orforglipron versus insulin glargine in people with type 2 diabetes and obesity or overweight at increased cardiovascular risk. The study enrolled 2,749 participants with primary endpoint of time to first major adverse cardiovascular event, completed in March 2026. Eli Lilly is positioning orforglipron as a cardiovascular outcomes option in high-risk populations, directly competing with established insulin therapy in this indication. This represents the first cardiovascular outcomes trial for orforglipron following its April 2026 FDA approval for type 2 diabetes.

GLP-1Type 2 diabetesWeight lossCardiovascularEli Lilly

Strategic Signal

PubMed28 Mar 2026JAMA cardiologyHigh impact● 8/10i

Cardiorenal Outcomes With Tirzepatide Compared With Dulaglutide in Patients With Diabetes and Cardiovascular Disease: A Post Hoc Analysis of the SURPASS-CVOT Randomized Clinical Trial.

Tirzepatide reduced a 6-component cardiorenal composite endpoint by 16% versus dulaglutide (23.7% vs 27.4%, HR 0.84) in people with type 2 diabetes and cardiovascular disease. Post hoc analysis of SURPASS-CVOT double-blind RCT, 13,165 patients, median 46.9 months follow-up. This provides the first head-to-head cardiorenal comparison between tirzepatide and a GLP-1 agonist in high-risk cardiovascular patients, extending beyond the primary non-inferiority finding. Gastrointestinal adverse events were higher with tirzepatide (42.5% vs 35.9%).

GLP-1CardiovascularKidneyType 2 diabetesDrug comparisonsEli LillyNovo Nordisk

Strategic Signal

Clinical Trial12 Mar 2026Phase 3High impact● 8/10i

The Cardiovascular Safety and Efficacy of Cagrilintide 2.4 mg s.c. in Combination With Semaglutide 2.4 mg s.c. (CagriSema 2.4 mg/2.4 mg s.c.) Once-weekly in Participants With Established Cardiovascular Disease

Phase 3 cardiovascular outcomes trial evaluating CagriSema (cagrilintide + semaglutide 2.4 mg/2.4 mg) versus placebo in people with established cardiovascular disease. 7,101 participants enrolled with up to 4.5 years follow-up, measuring time to first 3-point MACE (cardiovascular death, non-fatal MI, non-fatal stroke). Novo Nordisk is testing whether their dual amylin/GLP-1 combination can deliver cardiovascular benefits beyond current GLP-1 monotherapy in high-risk populations. This represents the first major cardiovascular outcomes trial for a dual incretin/amylin combination therapy.

GLP-1CardiovascularWeight lossNovo Nordisk

Strategic Signal

Clinical Trial12 Jan 2026Phase 3High impact● 8/10i

A Phase 3, Randomized, Double-blind, Placebo-Controlled Study to Investigate the Effect of Tirzepatide on the Reduction of Morbidity and Mortality in Adults With Obesity

Phase 3 cardiovascular outcomes trial testing tirzepatide versus placebo in 15,374 adults with obesity, measuring time to first major adverse cardiovascular event (death, MI, stroke, coronary revascularization, or heart failure). The randomized, double-blind, placebo-controlled study completed enrollment with expected results in October 2027. This represents Eli Lilly's bid to establish tirzepatide's cardiovascular benefits in obesity, directly competing with Novo Nordisk's Wegovy which gained MACE indication approval in March 2024. The massive enrollment suggests Lilly is positioning for a broad obesity cardiovascular claim to differentiate from Novo's narrower obesity plus established CVD indication.

GLP-1Weight lossCardiovascularEli LillyNovo Nordisk

Weekly briefing

Key signals, decoded for pharma executives and investors. Free, every week.

Questions? Book a consultation →